Paricalcitol (SPECIAL ACCESS PROGRAM)
Disclaimer: Official controlled document is the CHEO online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.
- Treatment and prevention of secondary hyperparathyroidism associated with chronic renal failure
Reconstitution and Stability:
- Available as a 5 microgram/mL solution for injection
- Store at room temperature
- Compatibility Information: none known
- Incompatible: heparin (see notes)
(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)
Infusion Time: 1 minute
Give via hemodialysis line at any time during dialysis
|IV Intermittent Infusion
|IV Continuous Infusion
(For neonatal dosages, refer to Neonatal IV Drug Manual.)
- 0.04 - 0.08 mcg/kg/dose 3 times a week, depending on initial ionized PTH
- Initial: 0.04 - 0.1 mcg/kg/dose up to 3 times per week (no more frequently than every 2 days)
- Maximum dose: 0.24 mcg/kg/dose
- hold or decrease dose if corrected serum calcium level is elevated or if Calcium x Phosphorous is greater than 6.1
Potential hazards of parenteral administration:
- nausea, vomiting, diarrhea (occasional)
- headache, chills, malaise, dizziness, lightheadedness (occasional)
- allergic reactions (rare) (pruritus, rash, urticaria, facial and oral edema)
- monitor serum calcium and phosphorous levels
- may be given anytime during dialysis
- Propylene glycol, an excipient in the solution can neutralize heparin
The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.
CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.
Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.